Close Menu
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
What's Hot

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Facebook X (Twitter) Instagram
subjectional.com
Subscribe
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
subjectional.com
Home » Sanofi hits $5 billion in third-quarter core profit on strong Dupixent and vaccine sales, raises forecast for 2024
Vaccines

Sanofi hits $5 billion in third-quarter core profit on strong Dupixent and vaccine sales, raises forecast for 2024

Paul E.By Paul E.October 25, 2024No Comments2 Mins Read
Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter operating profit of 4.61 billion euros ($4.99 billion), an increase of 14.4% year over year and 19.9% ​​at constant currency. I did.

The company reported third-quarter sales of 13.44 billion euros ($14.79 billion), beating the consensus of $13.97 billion.

Revenues increased 12.3% year over year, or 15.7% at constant currency, driven by strong growth in Dupixent, new pharmaceutical products, vaccines and Opera.

The French pharmaceutical company reported adjusted EPS of 2.86 euros or $1.57, an increase of 12.2% (17.6% excluding currency).

Sales of Sanofi’s blockbuster eczema drug Dupixent rose 23.8% to €3.48 billion.

Also read: FDA approves Regeneron/Sanofi blockbuster Dupixent for lung disease in smokers

New drug launches increased by 67.1% to €727 million, led by Altuviiio (hemophilia treatment), Nexviazyme (Pompe disease) and Rezurock (chronic graft-versus-host disease).

Vaccine sales increased by 25.5% to EUR 3.8 billion due to the phasing of influenza sales and additional production capacity approved by Bayfortas.

Beyfortus (RSV) sales were €645 million, driven by early deliveries in the US and rollout in several countries. In collaboration with manufacturing company AstraZeneca Plc (NASDAQ:AZN), the additional production capacity has made it possible to increase supply after a second external filling line was approved.

Opera, Sanofi’s consumer healthcare business unit, posted sales of 1.3 billion euros, an increase of 8%.

Guidance: Earlier this week, Sanofi updated its 2024 operating EPS guidance to at least low single digits at CER, supported by strong underlying performance, reflecting a new guidance range excluding Opera.

The company previously expected the company’s EPS to be stable excluding the impact of currency fluctuations.

The company reaffirmed that Dupixent will achieve sales of approximately 13 billion euros in 2024.

Sanofi expects influenza vaccine sales to decline by low single digits due to low vaccination rates. Vaccine sales in 2024 are expected to grow in the low single digits, compared to the mid-single digits previously.

Sanofi expects Bayfortas sales in the fourth quarter to be similar to the third quarter.

Price Action: SNY stock rose 2.82% during the pre-market session to $53.52 at last check on Friday.

Image by HJBC (via Shutterstock)

Read next:

Next step: Transform your trading with Benzinga Edge’s unique market trading ideas and tools. Click now to access exclusive insights that can give you an edge in today’s competitive market.

story continues



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleDeadly Israeli attack hits southern Gaza, health officials say: Latest information
Next Article 2 weeks from voting day
Paul E.
  • Website

Related Posts

Kentucky leaders emphasize whooping cough vaccination

October 31, 2024

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

October 31, 2024

Trust is important, but increasing vaccination rates also requires three things

October 31, 2024
Leave A Reply Cancel Reply

Latest Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Transport Secretary reveals overhaul of aging pneumatic transport systems

Latest Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Welcome to Subjectional!

At Subjectional, we believe that informed opinions are the foundation of a vibrant society. Our mission is to provide insightful, engaging, and balanced information across a diverse range of topics that matter to you. Whether you’re interested in the latest developments in health, navigating the complexities of politics, staying updated on sports, exploring technological advancements, or advancing your career, we’ve got you covered.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 subjectional. Designed by subjectional.

Type above and press Enter to search. Press Esc to cancel.